Abstract Details

Title Treatment Patterns of Biologic Therapies in a Real-world United States Myasthenia Gravis Population: A Claims Data Analysis

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P11 - Poster Session 11 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-013

Objective To describe treatment patterns of biologic therapies among newly treated patients with myasthenia gravis (MG).

Background Newer biologic therapies for MG (neonatal fragment crystallizable receptor blockers, C5 complement inhibitors, anti-CD20 therapies) aim to address unmet clinical needs; however, real-world evidence describing treatment patterns of these drugs is limited.

Design/Methods Data were drawn from the Merative™ MarketScan® databases from July 1, 2016–September 30, 2024. Continuous enrollment for ≥6 months before and ≥12 months after the earliest date of any MG treatment was required. Treatment patterns were examined among patients who received biologics.

Results Of 2,943 treated patients with MG, 219 had ≥1 claim for a biologic therapy (mean [SD] age, 57.5 [15.1] years; 53.4% male). The mean (SD) time from MG diagnosis to first use of a biologic (biologic index date) was 24.3 (20.9) months. Most patients (98.1%) initiated a biologic as a third- or later-line therapy. The mean (SD) biologic treatment duration was 5.4 (6.9) months, and 65.3% of patients used a biologic in combination with other treatment classes (acetylcholinesterase inhibitors, immunosuppressants, oral glucocorticoids [OG], intravenous immunoglobulin). More patients used OG in the 6 months prior to biologic index date (n=161; 73.5%) than during biologic treatment (n=90; 41.1%). Among patients using biologic therapy with OG, 78.9% (n=71) started on a medium/high OG dose (>5 mg/day prednisone equivalence) at initiation of the biologic, and of those, 38.0% (n=27) moved to low/maintenance dosing (≤5 mg/day prednisone equivalence) during biologic treatment. MG exacerbations and crises were observed in 35.6% and 1.4% of patients during biologic treatment, respectively.

Conclusions Biologic therapies were largely initiated as third- or later-line treatment, with a mean treatment duration of <6 months. Patients continued to experience exacerbations/crises and use OG during biologic treatment. These findings highlight the need for effective biologic therapies earlier in the disease course to improve clinical outcomes.

Authors/Disclosures
Lesley-Ann 9. Miller-Wilson, PhD (Immunovant) PRESENTER	Dr. Miller-Wilson has received personal compensation for serving as an employee of Immunovant Inc. Dr. Miller-Wilson has or had stock in Immunovant Inc..
Lincy Lal, PhD	Mrs. Lal has received personal compensation for serving as an employee of Immunovant. Mrs. Lal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with UT School of Public Health.
Nicole R. Princic, MS	Mrs. Princic has nothing to disclose.
Carolyn R. Lew, PhD	Dr. Lew has received personal compensation for serving as an employee of Merative.
Nicholas S. Streicher, MD	Dr. Streicher has nothing to disclose.
Yuriy Edwards, MD, PhD	Dr. Edwards has received personal compensation for serving as an employee of Immunovant. Dr. Edwards has stock in Immunovant.

��ɫ��

��ɫ��